Argenx
UCB preps filings for another challenger to AZ’s Soliris
Phil Taylor
Apellis Pharma, Argenx, AstraZeneca, myasthenia gravis, rozanolixizumab, Soliris, UCB, Ultomiris, zilucoplan
0 Comment
UCB chases after Argenx with FcRN drug for myasthenia gravis
Phil Taylor
Argenx, autoimmune disease, efgartigimod, myasthenia gravis, rozanolixizumab, UCB
0 Comment
J&J backs out of $1.6bn blood cancer antibody alliance with Argenx
Phil Taylor
acute myeloid leukaemia, Argenx, immuno-oncology, Johnson & Johnson, Oncology, partnering
0 Comment
AbbVie takes option on Argenx’s cancer immunotherapy
Richard Staines
AbbVie, Argenx, cancer immunotherapy
0 Comment
ARGX-115 is still in preclinical development